Guiford!!! Mittwoch gibt es Geschäftszahlen! - 500 Beiträge pro Seite

[ttaa]

Mittwoch ist es soweit! Es gibt die ersten Zahlen im neuen Jahr! Analysten sehen einen deutliches Umsatzplus. Zudem sind sie sehr,sehr gut gestimmt.Nun rann an die Aktien WKN: 894167. Wer nicht kauft ist selber Schuld. Kauf bis 45 Euro!! Merill Lynch nennt Kursziel 130 Euro auf Seite www.nasdaq.com! Brandheißer Tipp! Kauft solange der Kurs noch nicht ausgebrochen ist!!!

[Coluche]

Hi ttaa,
woher weißt du, daß es Mittwoch neue Zahlen gibt ?

Überlege mir schon eine Weile, ob ich da reingehen soll.

[Zocker99]

Ich wollte Guilford letzte Woche auch kaufen, habe mich aber dann für
Enzon (873 997) aufgrund des Biotec-Reports entschieden.(Entscheidung bisher nich bereut => + 30 %)

Wenn Deine Infos seriös sind, sollte man sich wirklich überlegen Guilford ins Depot zu nehmen.

[Coluche]

Taipan hat sie im Februar empfohlen, Sturza`s Medical Letter im Januar nochmals, nach Empfehlung i. Sept.99. empfehlen sie aktuell aber nur unter $ 28.

[Lindwurm]

Hallo an alle,

Hier noch ein Artikel der "Washington Post" zum Thema Guilford:

TECH INVESTOR Guilford Joins Md. Biotech Highfliers
By Jerry Knight Washington Post Staff Writer Thursday, January 20, 2000; Page E05

This may be the Internet Millennium, but it`s biotechnology month in the stock market, with three Maryland biotech stocks hitting 52-week highs yesterday.

MedImmune Inc. of Gaithersburg was up $16.31 1/4, to $178, EntreMed Inc. of Rockville gained $5.50, to $46.87 1/2, and Baltimore`s Guilford Pharmaceuticals Inc. closed up $2.75 at $27.87 1/2.

"There`s general enthusiasm for the biotech sector," said Scott Koonce of Koonce Securities in Rockville.

Institutional investors and fund managers are starting the year by adding new stocks to their biotech portfolios, branching out from established names such as MedImmune and EntreMed.

Guilford has joined the group not only because the biotech rally seems to be broadening, but also because the firm has announced three important developments--involving three different products, said Guilford communications director Stacey Jurchison.

Yesterday Guilford executives told their story to another group of potential investors at a conference in New York sponsored by First Union Securities.

While many biotech firms are pursuing a single avenue of research, Guilford is going down a pair of paths, focusing on drug-delivery systems for fighting cancer as well as a cluster of neurological drugs.

On the drug-delivery side, Guilford recently began a new round of tests involving 240 patients for its treatment for brain tumors. To create a time-release tumor treatment, Guilford packs chemotherapy drugs into a little biodegradable wafer that`s implanted in the cavity left when a tumor is removed surgically. Already used for recurrent tumors, the wafer is now being tried as a first-time treatment.

In December, Guilford announced another drug-delivery research initiative by filing a request to test a new ovarian cancer treatment that packs the drug Taxol into tiny "microspheres" that can be injected into the body.

Guilford was one of 11 firms whose Taxol research was detailed in a year-end report by Sturza`s Institutional Research, a New York firm that specializes in medical stocks. Taxol is now the largest-selling anti-cancer drug, generating sales of about $1.5 billion last year, the study noted.

And in partnership with the big biotech firm Amgen Inc., Guilford is getting ready for the second phase of trials of a drug that treats Parkinson`s disease by stimulating the regrowth of neuron cells deep in the brain.

"What I like about them is that they are not just a one-product deal. They`ve got a research pipeline of four or five different products they`re working on," Koonce said. "If any one of them hits, the stock could take off."

Koonce said Guilford`s shares didn`t catch the biotech wave when it began to rise last year because investors were focused mostly in genomics and antibody research. "Everything else kind of languished."

Guilford still reports regular losses but its finances have matured beyond the cash-burning stage that`s common in biotech.

The company`s picked up a $5 million payment from Amgen in December and its brain tumor wafers are generating about $20 million in sales via a pair of big drug company partners. Jurchison said about 35 percent of that flows directly to Guilford, which manufactures the product and collects royalties on its research.

Guilford`s balance sheet also is unusual by biotech standards--showing $145 million in cash. Roughly one-third of that came in last September when the firm sold $45 million worth of stock in a private placement managed by Prudential Vector Healthcare Group.

The institutions that bought those 3.4 million shares must be among the investors most satisfied with the recent run-up in Guilford stock. They paid just $13.50 a share for their stock and have doubled their money in less than four months.

Quelle:
http://www.washingtonpost.com/wp-srv/WPlate/2000-01/20/248l-…

+Grüsse